Gilotrif (afatinib) — United Healthcare

Initial criteria

• Diagnosis of advanced, non-nasopharyngeal head and neck cancer
• AND Disease has progressed on or after platinum-containing chemotherapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Gilotrif therapy

Approval duration

12 months